Navigation Links
Almac has Successful MHRA Inspection at its Clinical Services UK Site
Date:10/17/2010

Almac has Successful MHRA Inspection at its Clinical Services UK Site -- CRAIGAVON, Northern Ireland, October 18, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biometrics, Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Corporate Expansion, New Products & Services, European Government Click to view news release full screen  

Almac has Successful MHRA Inspection at its Clinical Services UK Site

 

CRAIGAVON, Northern Ireland, October 18, 2010 /PRNewswire/ -- Almac is once again pleased to announce the successful completion of an inspection of its Clinical Services UK facility located in Craigavon by the Medicines and Healthcare products Regulatory Agency (MHRA).

The routine inspection, which took place over four days, from September 13th - September 16th, was conducted by a MHRA inspector who concluded that the site continues to be compliant with EU Good Manufacturing Practices, with no critical or major failures observed.

Commenting on the inspection, Paul O'Connor (Vice President, Quality), said:

"We are extremely pleased with the outcome of our inspection. These successful results are a positive reflection of all the investment Almac has made over the past few years in our facilities and recruitment of the best employees, ensuring that we are a market leader and continue to deliver a high quality service. Quality is at the core of our ethos - we have three MHRA approved facilities globally, including our additional FDA assessed US facilities in Audubon, Pennsylvania and Durham, North Carolina. The very high standards of quality compliance will continue with our new $120 million North American Headquarters in Souderton - scheduled to open during the autumn."

Notes to Editors

About Almac:

The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.

The company employs over 2,800 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Almac has officially gained full possession of its new $120m North American Headquarters, which started in July 2008, and employees will relocate during the fall.

For more information on Almac, please visit http://www.almacgroup.com Contact: Aileen Murphy aileen.murphy@almacgroup.com Tel: +44(0)28-3836-2436
'/>"/>

SOURCE Almac Group
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. University of Nevada, Reno, demonstrates successful sludge-to-power research
2. University of Nevada, Reno demonstrates successful sludge-to-power research
3. New method successfully predicted how oil from Deepwater Horizon spill would spread
4. School-based intervention successfully lowers drinking rates in at risk children
5. Scientists successfully use human induced pluripotent stem cells to treat Parkinsons in rodents
6. Pitt researcher says simple polymer-based filter successfully cleans water, recovers oil in Gulf of Mexico tests
7. Polymer-based filter successfully cleans water, recovers oil in Gulf of Mexico test
8. Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
9. Novel protein essential for successful pregnancy
10. Successful launch for ESAs CryoSat-2 ice satellite
11. Successful genome sequencing of pea aphid is a breakthrough for ecology and agricultural research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to ... and meaningful advances worldwide, The Japan Prize Foundation ... Prize, who have pushed the envelope in their ... and Communication. Three scientists are being recognized with ... achievements that not only contribute to the advancement ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring ... home or in healthcare facilities during periods of rest. A lightweight, non-invasive monitor ...
(Date:2/23/2017)... LOS ANGELES , Feb. 23, 2017  Capricor Therapeutics, ... cardiac and other medical conditions, today announced that Linda Marbán, ... at two upcoming investor conferences: Cowen ... 2017 at 10:00 am ET Boston, MA ... 14, 2017 at 9:00 am PT (12:00 pm ET) ...
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... ... announced that is has acquired Kendall Research Systems, LLC (KRS) clinical ... (MIT) that develops neural interface technology for research and clinical applications. The terms ...
Breaking Biology Technology: